TB Alliance Launches Five-Country Phase 2 Clinical Trial Evaluating Next-Generation TB Drug
Early results presented at the Union World Conference on Lung Health suggest promise of new compound to fight tuberculosis that […]
News
News
High Cure Rate with Drug-Resistant TB Regimen: Results of Operational Research in Central and Southeast Asia
Indonesia, Kyrgyzstan, Philippines, Ukraine, Uzbekistan, and Vietnam presented results of LIFT-TB operational research program at the Union Conference on Lung
TB Alliance Applauds Macleods’ Launch of a Key Component of WHO-Recommended Drug-Resistant TB Treatment Regimen
NEW YORK (November 13, 2023)—Indian pharmaceutical company Macleods has become the second manufacturer to launch pretomanid, a new medicine and
New Drug-Resistant TB Treatments Reach Patients in Pakistan as Association for Social Development Accelerates Pilot Implementation
ISLAMABAD and PRETORIA (9 November 2023)—The Association for Social Development (ASD) has registered 206 participants with drug-resistant tuberculosis (DR-TB) in
New WHO Global TB Report Shows Recovery in Effort to Combat TB, But Stronger Investments are Needed to Help Reach UN Goals
“We are heartened to see that progress against tuberculosis (TB) has started to rebound after several years of increased numbers
World Leaders Cite the Benefit and Importance of New, Six-Month Drug-Resistant TB Treatment at United Nations High-Level Meeting on Tuberculosis
The 2023 United Nations (UN) High-Level Meeting (HLM) on Tuberculosis (TB) saw world leaders come together to commit to increased
UN Commitment on Tuberculosis Needs Leadership to Match Ambition
TB Alliance wholeheartedly supports the commitment made today at the United Nations High-Level Meeting on Tuberculosis (TB) to fight this
Kyrgyzstan, Ukraine, and Uzbekistan Update National Guidelines for Drug-Resistant TB Treatment to Advance National Rollout of Three-Drug, Six-Month Regimen
NEW YORK (September 15, 2023) — Kyrgyzstan, Ukraine, and Uzbekistan — participants in the LIFT-TB project — have updated their
Realizing our “Triple-A Mandate”
Four years ago, TB Alliance secured the first regulatory approval from the United States Food and Drug Administration (US FDA)
TB Alliance Announces Partnership with Remington Pharmaceuticals to Commercialize New Therapy for Drug-Resistant Forms of TB in Pakistan
NEW YORK (August 10, 2023)—Non-profit drug developer TB Alliance has granted Remington Pharmaceutical Industries (Pvt.) Ltd. a non-royalty bearing license